380
Participants
Start Date
February 22, 2018
Primary Completion Date
March 8, 2019
Study Completion Date
September 26, 2019
Tralokinumab
Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.
Placebo
Placebo contains the same excipients in the same concentration only lacking tralokinumab.
Universitair ziekenhuis Brussel, Brussels
Cliniques Universitaires St-Luc, Brussels
University Hospital Antwerp, Antwerp
LEO Pharma Investigational Site, Loverval
Radboud MC, Nijmegen
Mount Sinai West Dermatoogy, New York
Interdisciplinary Study Association GmbH, Berlin
MensingDerma Research GmbH, Hamburg
Universitätshautklinik Kiel, Kiel
Wake Research, Raleigh
Fundación Hospital Alcorcón, Madrid
National Allergy and Asthma Research, LLC, North Charleston
Medical Dermatology Specialists, Atlanta
International Dermatology Research, Miami
L & C Professional Medical Research, Miami
Lenus Research & Medical Group, Sweetwater
Olympian Clinical Research, Tampa
University of Alabama-Birmingham, Birmingham
Hospital de Pontevedra, Pontevedra
Dermatologists of Greater Columbus, Bexley
St. Josef-Hospital, Ruhr-Universitet, Bochum
Hospital General de Valencia, Valencia
Indiana Clinical Trials Center, Plainfield
Respiratory Medicine Research, Ypsilanti
Klinik und Poliklinik für Dermatologie und Allergologie, Bonn
Klinikum der Johann Wolfgang Goethe-Universität Klinik, Frankfurt am Main
Northwestern University, Chicago
Universitätsklinikum Tübingen, Tübingen
Dermatology Research Associates, Los Angeles
Clinical Science Institute, Santa Monica
California Dermatology & Clinical Research Institute, Encinitas
First OC Dermatology, Fountain Valley
Center for Dermatology Clinical Research, Fremont
Oregon Dermatology & Research, Portland
Danbury Clinical Research, Danbury
Study Center, Bangor
Institute for Skin Advancement, Calgary
Skin Care Centre, Vancouver
Maritime Medical Research Centre, Bathurst
Eastern Canada Cutaneous Research, Halifax
CCA Medical Research, Ajax
Simcoderm Medical and Surgical Dermatology Centre, Barrie
DermEdge Research, Mississauga
York Dermatology Center, Richmond Hill
Research Toronto, Toronto
XLR8 Medical Research, Windsor
Universitätsklinikum Jena, Jena
Amcademic Medical Center, Amsterdam
LEO Pharma Investigational Site, Bergen op Zoom
LEO Pharma Investigational Site, Groningen
Erasmus MC, Rotterdam, Rotterdam
University Medical Centre Utrecht, Utrecht
Nzoz Med-Laser, Lublin
LEO Pharma Investigational Site, Rzeszów
Wojskowy Instytut Medyczny, Warsaw
Wromedica s.c., Wroclaw
Derm Medica Sp.zo.o., Wroclaw
Hospital General de Alicante, Alicante
Hospital Universitari de Bellvitge, Barcelona
Addenbooke's Hospital, Cambridge
The Princess Alexandra Hospital, Harlow
East Surrey Hospital, Redhill
Queen Elizabeth Hospital Birmingham, Birmingham
Russells Hall Hospital, Dudley
The Royal Free Hospital, London
Guy's and St Thomas' NHS Foundation Trust, London
Lead Sponsor
LEO Pharma
INDUSTRY